Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age2-12
SponsorTongji Hospital
About this trial
To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.
Eligibility criteria
Qualifiers
Aged 2-12 years
ASA physical status I-II
Body mass index (BMI): 14-28 kg/m²
Scheduled for elective tonsillectomy with or without adenoidectomy
Disqualifiers
History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA)
Previous episodes of significant PRAEs
Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol)
Comorbidities including: Uncorrected congenital heart disease, neuromuscular disorders, Developmental delay, Abnormal hepatic/renal function
Trial design
Treatments tested in this trial
- Remimazolam
- Propofol
- Ciprofol
Treatment groups
114 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov